Market closed
C4 Therapeutics/$CCCC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About C4 Therapeutics
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
Ticker
$CCCC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
145
Website
C4 Therapeutics Metrics
BasicAdvanced
$279M
Market cap
-
P/E ratio
-$1.63
EPS
3.05
Beta
-
Dividend rate
Price and volume
Market cap
$279M
Beta
3.05
52-week high
$11.88
52-week low
$3.61
Average daily volume
1.6M
Financial strength
Current ratio
6.311
Quick ratio
6.144
Long term debt to equity
25.329
Total debt to equity
27.65
Management effectiveness
Return on assets (TTM)
-20.61%
Return on equity (TTM)
-46.00%
Valuation
Price to revenue (TTM)
7.571
Price to book
1.15
Price to tangible book (TTM)
1.15
Price to free cash flow (TTM)
-3.561
Growth
Revenue change (TTM)
65.45%
Earnings per share change (TTM)
-40.62%
3-year revenue growth (CAGR)
-0.30%
3-year earnings per share growth (CAGR)
-3.26%
What the Analysts think about C4 Therapeutics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for C4 Therapeutics stock.
C4 Therapeutics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
C4 Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
C4 Therapeutics News
AllArticlesVideos
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
GlobeNewsWire·2 weeks ago
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
GlobeNewsWire·1 month ago
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for C4 Therapeutics stock?
C4 Therapeutics (CCCC) has a market cap of $279M as of December 24, 2024.
What is the P/E ratio for C4 Therapeutics stock?
The price to earnings (P/E) ratio for C4 Therapeutics (CCCC) stock is 0 as of December 24, 2024.
Does C4 Therapeutics stock pay dividends?
No, C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders as of December 24, 2024.
When is the next C4 Therapeutics dividend payment date?
C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders.
What is the beta indicator for C4 Therapeutics?
C4 Therapeutics (CCCC) has a beta rating of 3.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.